GPT and fatty liver disease: This study demonstrated reductions in fibrosis scores, hepatic steatosis (up to −21.3%), ALT (up to −13.6 U/L), AST (up to −10.2 U/L), GGT (up to −21.8 U/L), HbA1c (up to −0.2% points), and HOMA-IR (up to −0.21 units), highlighting its potential for targeting insulin resistance and hepatic injury in patients with biopsy-proven MASLD [84,85].